Company profile: Xanadu Bio
1.1 - Company Overview
Company description
- Provider of nanoparticle delivery technology for mRNA and other nucleic acids, using PACE platform technology.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xanadu Bio
MannKind
HQ: United States
Website
- Description: Provider of inhaled and wearable therapeutic products and platforms for diabetes and pulmonary diseases, including Afrezza (inhaled insulin), Tyvaso DPI (treprostinil for PAH and PH-ILD), Clofazimine Inhalation Suspension (for NTM lung disease), Nintedanib DPI (for pulmonary fibrotic diseases), V-Go (wearable insulin delivery), and Technosphere Technology for dry powder inhalation formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MannKind company profile →
Cellectar Biosciences
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer therapies and diagnostics, designing phospholipid drug conjugates that target tumor cells to detect, treat, and monitor cancers. Lead candidate iopofosine I 131 is in Phase 2/1 studies. Pipeline includes CLR 1900 cytotoxic compounds and collaborative PDC programs (CLR 2000, CLR 12120) with Avicenna and Orano Med, plus new PDCs with IntoCell and LegoChemBio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellectar Biosciences company profile →
Acorda Therapeutics
HQ: United States
Website
- Description: Provider of commercial-stage biopharmaceutical therapies, identifying, developing and commercializing therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other nervous system disorders. Products include INBRIJA (levodopa inhalation powder for Parkinson’s symptoms), AMPYRA (dalfampridine to improve walking in adults with MS), and the ARCUS drug delivery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acorda Therapeutics company profile →
Sancilio & Company
HQ: United States
Website
- Description: Provider of biopharmaceutical products and services, including cardiovascular and dental health offerings such as OCEAN BLUE PROFESSIONAL OMEGA-3 2100 and LUDENT; plus startup guidance, compound discovery and synthesis, FDA and EMA-compliant analytical support, dual-facility stability studies, formulation development, and FDA-guideline drug manufacturing across dosage forms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sancilio & Company company profile →
Lipocine
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products, including TLANDO, an FDA-approved oral testosterone replacement therapy; LPCN 1111, an oral testosterone prodrug for hypogonadal men; LPCN 1144 and 1148, oral prodrugs of bioidentical testosterone for NASH and cirrhosis symptoms; LPCN 1107, an oral candidate to prevent recurrent preterm birth (FDA orphan drug); and LPCN 1154, an oral neurosteroid for postpartum depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lipocine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xanadu Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xanadu Bio
2.2 - Growth funds investing in similar companies to Xanadu Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xanadu Bio
4.2 - Public trading comparable groups for Xanadu Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →